Cargando…
Heteroarotinoids with Anti-Cancer Activity Against Ovarian Cancer Cells
The Flex-Het compound 10a (SHetA2-NSC 721689) {[4-nitrophenylamino][(2,2,4,4-tetramethylthiochroman-6-yl)amino]methane-1-thione]} has shown promise in preclinical testing as an anti-cancer agent without evidence of toxicity, skin irritancy, or teratogenicity. One objective of this study was to synth...
Autores principales: | Le, Thanh C., Berlin, K. Darrell, Benson, Stacy D., Eastman, Margaret A., Bell-Eunice, Gianna, Nelson, Anna C., Benbrook, Doris M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709466/ https://www.ncbi.nlm.nih.gov/pubmed/19662136 http://dx.doi.org/10.2174/1874104500701010011 |
Ejemplares similares
-
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo
por: Myers, Tashanna, et al.
Publicado: (2008) -
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2
por: Sharma, Ankur, et al.
Publicado: (2018) -
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres
por: Benbrook, Doris Mangiaracina, et al.
Publicado: (2013) -
SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention
por: Benbrook, Doris Mangiaracina
Publicado: (2022) -
Targeting autophagy in cancer management – strategies and developments
por: Ozpolat, Bulent, et al.
Publicado: (2015)